Mallinckrodt Pharma Offers Presentation of 11 Posters Show Data on MNK-155 and XARTEMIS XR at PAINWeek

Mallinckrodt MNK presented 11 posters with data on its investigational opioid, MNK-155, an extended-release oral formulation of hydrocodone and acetaminophen, and recently FDA-approved XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets (CII), at PAINWeek, September 2-6 in Las Vegas, Nevada. The studies examined the compound's efficacy, safety, abuse-related characteristics and release/delivery profiles with immediate- and extended-release components. MNK-155 is an investigational extended-release oral formulation of hydrocodone and acetaminophen being studied for the management of moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate. XARTEMIS XR is the first and only immediate- and extended-release oral combination of two clinically proven pain medications - oxycodone and acetaminophen, and is indicated for the management of acute pain severe enough to require opioid treatment and in patients for whom alternative treatment options (e.g., non-opioid analgesics) are ineffective, not tolerated or would otherwise be inadequate.